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Abstract 
Cluster of pneumonia infection emerged in Wuhan, China due to severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2). Additionally, more than 190 countries have confirmed 82 million cases 
of SARS-CoV-2 infection. Currently, there is a SARS-CoV-2 epidemic, and no effective prophylactic 
methods are available. A vaccine is considered as an effective method to restrict an epidemic. Several 
vaccine designing techniques have been established, which is enabling researchers from various institutes 
for developing vaccine towards SARS-CoV-2 infections. In this review, we condense the development of 
vaccine research against SARS-CoV-2.
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Introduction
A cluster of pneumonia infections emerged in 
Wuhan Hospital, China which started from December 
2019 up to now. The infection was reported to be 
caused due to a type of beta-coronavirus, which named 
by World Health Organization (WHO) as severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2)1,2. 
As per reports till March 26th 2021, the pathogen had 
infected more than 120 million individuals and caused 
2.7 million deaths worldwide1.
SARS-CoV-2 had a material genetic of positive-
stranded RNA and belongs to Betacoronavirus genera. 
Studies have revealed that SARS-CoV-2 genome consists 
of 29,700 nucleotides, and shares approximately 79.5% 
similarity to the genome of SARS-CoV3,4. Furthermore, 
SARS-CoV-2 is known to have an ORF1ab polyprotein 
at the 5′-end which had a role in coding for viral non-
structural proteins. Genes at 3′-end had been known 
to encode the structural proteins such as spike (S), 
nucleocapsid (N), membrane (M), and envelope (E)5,6. 
Several studies have reported that SARS-CoV-2 binds 
to angiotensin converting enzyme 2 (ACE2) receptor on 
the host cell. The receptor played a key role in viral entry 
mechanism and related pathogenesis7,8 (Figure 1).
A vaccine is considered as an effective method 
which had high economic significance to restrict an 
infectious disease outbreak3,9. The use of vaccines 
inducing neutralizing antibodies is the best option to 
increase the number of populations that are immune to 
SARS-CoV-210. Thus, the development of SARS-CoV-2 
vaccine became an essential need. As per few reports, 
about 40 pharmaceutical companies and academic 
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program for developing vaccines towards SARS-CoV-2. Therefore, we summarize the ongoing advance research in 
development of SARS-CoV-2 vaccine. 
Figure 1. Structural part of SARS-CoV-2. The virion consists of spike glycoprotein (S), membrane protein 
(M), envelope protein (E), and nucleocapsid protein (N). 
Antigenic Retrieval and Selection from SARS-
CoV-2 Structural Protein
Various non-srtructural protein is common to be 
utilized for vaccine development. However, spike protein 
(S protein) is widely being investigated to be used for 
developing a vaccine against SARS-CoV-2. Studies have 
revealed that it is a viral surface protein, which is directly 
recognized by the host immune system3,4. Subsequently, 
it has been reported that S protein acts as a mediator for 
interaction between virus and host cell by binding to 
ACE2 receptor, and cause consequent pathogenicity11. 
The homologous structure of S protein is being used for 
vaccine development, which has proven to be effective 
in overcoming the previous outbreaks including SARS-
CoV and Middle East respiratory syndrome coronavirus 
(MERS-CoV)12.
The S protein monomer consists of 1273 amino 
acids in length and molecular weight about 140 kDa. 
Furthermore, it has ability to undergo the self-association 
mechanism and formed a homotrimer structure as a 
special feature of class I viral fusion protein. Structural 
studies showed that S protein is composed of two 
subunits, termed as S1 and S2 part. The S1 subunit 
can be organized into two domains, such as N-terminal 
domain (NTD) and C-terminal domain (CTD). In brief, 
the CTD is reported as receptor-binding domain (RBD). 
On the other hand, the S2 subunit had an essential 
part for membrane fusion which consist of internal 
membrane fusion peptide (FP), two heptad repeats 
(HR), membrane proximal external region (MPER), and 
transmembrane domain (TM)13,14. Recently, the S trimer 
structure of SARS-CoV-2 within the pre-fusion stage, 
and the RBD structure in convolution with ACE2 had 
been successfully determined15. 
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Figure 2. Brief structure of SARS-CoV-2 spike glycoprotein. 
The S trimer protein structure had been reported 
to act as an epitope and had ability to induce a high 
immunogenicity. Coleman et al. showed that the S 
trimer protein could be produced within baculovirus 
insect cells, and it could be transformed into 
nanoparticles16. Furthermore, it was formulated with an 
adjuvant (alum) and injected into the mice. Moreover, 
the immunized mice were observed to obtain the 
data about titers level of specifi c antibodies after the 
nanoparticle administration16,17. Recently, the Clover 
Biopharmaceutical has announced that they have 
designed SARS-CoV-2 S-trimer based-vaccine which 
processed into the preclinical testing stage9.
RBD has been known to interact directly with 
ACE2 receptors of the host cells. Thus, many studies 
have suggested RBD for immunization to investigate 
the antibody formation. It estimated for having ability 
to inhibit the viral recognition of ACE2 receptor, and 
prevent the subsequent pathogenesis18,19. Accordingly, 
many RBD-antigens based SARS-CoV-2 subunit 
vaccines are currently being developed. A study showed 
that the recombinant RBD, which was isolated from 
different types of virus serotypes, could trigger the 
multi-conformational by neutralizing antibodies towards 
SARS-CoV-2. This might be due to the presence of 
multiple epitopes that are recognized by specifi c immune 
systems20. 
As previously reported, S1 subunit has RBD as well 
as NTD, which suggests its role in binding S protein 
to the host receptor21. Subsequently, these domains 
can be widely utilized for vaccine development. As 
comparison, previous studies showed that MERS-
SoV S1 subunit with MF59 adjuvant could protect the 
human dipeptidyl peptidase 4 transgenic (hDPP4-Tg) 
mice against infections22. Furthermore, FP in S2 subunit 
has been reported to be involved in membrane fusion 
which is essential step for viral pathogenicity23,24. At 
present, Tianjin University is constructing RDB-FB-
based vaccines and producing high titers of neutralizing 
antibodies in mice9. 
In other hand, N protein is abundantly expressed 
by the coronavirus and it has molecular weight about 
50 kDa. It has been reported for promoting several 
functions such as nucleocapsid formation, initiation 
of viral budding transduction signal, RNA replication, 
and mRNA transcription25,26. Furthermore, N protein 
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has been suggested to have high antigenicity as about 
80% of patients with COVID-19 have been observed to 
produce antibodies specific to SARS-CoV N protein27.
Moreover, they have been observed to significantly 
reduce the viral load of vaccinia virus28. In addition, 
previous studies reported that bronchitis virus-related 
N protein could induce the activation of cytotoxic 
T lymphocytes (CTLs) by attenuating infection and 
thereby, protecting lungs from viral pathogenicity29,30.
Moreover, M protein is a glycoprotein located 
in the transmembrane of virus and it has molecular 
weight about 25 kDa. In brief, it has a crucial role for 
viral assembly. Furthermore, previous report exhibited 
that it abundantly expressed on the viral surface31,32. 
Full length M protein has been previously evaluated 
as a vaccine, which is reported could be neutralizing 
antibodies in patients with SARS. M proteins also 
consisted T cell epitope clusters and it was evaluated to 
be immunogenic33,34. In addition, it also identified for 
having high conserved domain32,35.
E protein has been reported to have about 76-
109 amino acids from studies in different types of 
coronaviruses. Moreover, it has been demonstrated 
to have limited immunogenicity compared to S, N, 
and M proteins. Thus, E protein is not predicted as an 
immunogen. However, E protein knockout models 
have been observed to significantly reduce secretion of 
inflammatory cytokine such as interleukin 1β (IL-1β), 
tumor necrosis factor (TNF), and IL-636. 
Recent Developments in SARS-CoV-2 Vaccine 
Technology
Studies have shown that whole-cell killed or live-
attenuated vaccine exhibit all antigenic components 
to the host and it could potentially trigger different 
immunological responses to fight the pathogen37,38. 
Traditional vaccines could be developed using advanced 
technology to design the foremost SARS-CoV-2 vaccine 
that may have prompt applications in healthcare. 
Wuhan Institute of Virology, Chinese Academy of 
Sciences, Zhejiang University, and other companies 
have successfully isolated SARS-CoV-2 and they have 
started developing vaccines. Recently, Codagenix Inc. 
collaborated with Serum Institute of India Ltd. developed 
live-attenuated SARS-CoV-2 vaccine9.
Vaccine subunits that comprise of more than one 
antigen with high immunogenicity could trigger the host 
immune response. Good quality of vaccines should be 
safe and easy to produce; however, it commonly requires 
adjuvants to exhibit the strong immune response39. 
Several companies have established programs to develop 
SARS-CoV-2 subunit-based vaccine, and most of them 
have been reported utilizing protein S as an antigen. 
The utilization of “molecular clamp” technology by 
University of Queensland and “Trimer-Tag” technology 
by Clover Biopharmaceuticals Inc. are several examples 
of subunit vaccines. Recently, Novavx Inc. announced 
nanotechnology-based vaccine candidates that have 
been evaluated in animal models while further testing 
in humans is needed. Furthermore, Pasteur Institute has 
collaborated with Chongqing Zhifei Biology Co. Ltd. 
and started developing SARS-CoV-2 subunit-based 
vaccine9,40.
Advanced technology in the synthesis, modification, 
and delivery of mRNA vaccines has been developed 
for past two decades. The mRNA vaccine is a notable 
alternative for conventional vaccine since it known for 
remarkable efficiency, fast production, low cost, and 
safe consumption41,42. In general, the mRNA vaccine 
development consists of several steps, including 
antigen selection, sequence optimization, nucleotide 
modification, delivery system, evaluation of immune 
response, and evaluating vaccine safety43. Recently, 
the mRNA vaccine against SARS-CoV-2 had been 
developed by Moderna and it is qualified for further 
analysis. Similarly, the mRNA vaccine based on protein 
S and RBD is being assessed into in vivo study under the 
collaboration of Fudan University, Shanghai Jiaotong 
University, and Bluebird Biopharmaceutical9.
Heterologous antigen expression is the principal 
action for live vector vaccines. It commonly produces 
stronger immunogenicity and trigger higher cellular 
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immunity44. Houston-based Greffex Inc. has been 
successful in developing live vector-based SARS-CoV-2 
vaccine using adenovirus vectors, and it is evaluated in 
animals. Moreover, Tonix Pharmaceuticals has recently 
announced the development of SARS-CoV-2 vaccine 
using Horsepox Virus (TNX-1800)9.
Another kind of vaccine, such as synthetic peptide-
based vaccines are also developed. It generated from 
small fragments or peptides which synthesized through 
chemically process. However, it has been reported that 
it exhibited a low immunogenicity effect due to the low 
molecular weight and complex structure. As a result, 
synthetic peptide vaccines require a few modifications, 
such as structural modification, presence of a delivery 
system, and adjuvants formulation45. Currently, 
researchers from Hong Kong University of Science and 
Technology are developing a peptide vaccine based on 
B and T cell epitopes from S and N proteins of SARS-
CoV46. 
Conclusion
We hope that several vaccines that have been 
developed could be used as an effective treatment for 
COVID-19 outbreak. Different methodology of vaccine 
development had both advantages and disadvantages. 
Furthermore, current advancements in technology 
may assist researchers to contribute in development of 
SARS-CoV-2 vaccine. 
Conflict of Interest: The author declare that they 
have no conflict of interest. 
Source of Funding: Faculty of Biotechnology, 
University of Surabaya, Indonesia and Generasi Biologi 
Indonesia Foundation, Indonesia. 
Acknowledgements: We thank Editage for editing 
the manuscript. 
Ethical Approval: None. 
References
1.  Zhu N, Zhang D, Wang W, et al. A Novel 
Coronavirus from Patients with Pneumonia in 
China, 2019. N Engl J Med. 2020;382(8):727-733. 
2.  Hui DS, I Azhar E, Madani TA, et al. The 
continuing 2019-nCoV epidemic threat of novel 
coronaviruses to global health — The latest 2019 
novel coronavirus outbreak in Wuhan, China. Int J 
Infect Dis. 2020;91:264-266. 
3.  Kharisma VD, Ansori ANM. Construction of 
Epitope-Based Peptide Vaccine Against SARS-
CoV-2: Immunoinformatics Study. J Pure Appl 
Microbiol. 2020;14(suppl 1):999-1005. 
4.  Ansori ANM, Kharisma VD, Muttaqin SS, Antonius 
Y, Parikesit AA. Genetic Variant of SARS-CoV-2 
Isolates in Indonesia: Spike Glycoprotein Gene. J 
Pure Appl Microbiol. 2020;14(suppl 1):971-978.
5.  Khailany RA, Safdar M, Ozaslan M. Genomic 
characterization of a novel SARS-CoV-2. Gene 
Rep. 2020;19:100682.
6.  Phan T. Novel coronavirus: From discovery 
to clinical diagnostics. Infect Genet Evol. 
2020;79:104211.
7.  Zhang H, Penninger JM, Li Y, Zhong N, Slutsky 
AS. Angiotensin-converting enzyme 2 (ACE2) as a 
SARS-CoV-2 receptor: molecular mechanisms and 
potential therapeutic target. Intensive Care Med. 
2020;46(4):586-590.
8.  Wina Nurtias LY, Turista DDR, Puspitasari 
E. Human immune response to SARS-CoV-2 
infection. J Teknol Lab. 2020;9(1):29-40.
9.  Zhang J, Zeng H, Gu J, Li H, Zheng L, Zou Q. 
Progress and Prospects on Vaccine Development 
against SARS-CoV-2. Vaccines. 2020;8(2):153.
10.  Speiser DE, Bachmann MF. COVID-19: 
Mechanisms of Vaccination and Immunity. 
Vaccines. 2020;8(3):404.
11.  Padron-Regalado E. Vaccines for SARS-CoV-2: 
Lessons from Other Coronavirus Strains. Infect Dis 
Ther. 2020;9(2):255-274. 
12.  Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The 
spike protein of SARS-CoV — a target for vaccine 
and therapeutic development. Nat Rev Microbiol. 
2009;7(3):226-236. 
13.  Wang Q, Zhang Y, Wu L, et al. Structural and 
Functional Basis of SARS-CoV-2 Entry by Using 
Human ACE2. Cell. 2020;181(4):894-904.e9.
14.  Li F. Structure, Function, and Evolution of 
Coronavirus Spike Proteins. Annu Rev Virol. 
2016;3(1):237-261. 
2802    Indian Journal of Forensic Medicine & Toxicology, October-December 2021, Vol. 15, No. 4
15.  Wrapp D, Wang N, Corbett KS, et al. Cryo-EM 
structure of the 2019-nCoV spike in the prefusion 
conformation. Science. 2020;367(6483):1260-
1263.
16.  Coleman CM, Liu YV, Mu H, et al. Purified 
coronavirus spike protein nanoparticles induce 
coronavirus neutralizing antibodies in mice. 
Vaccine. 2014;32(26):3169-3174. 
17.  Muthumani K, Falzarano D, Reuschel EL, et al. A 
synthetic consensus anti–spike protein DNA vaccine 
induces protective immunity against Middle East 
respiratory syndrome coronavirus in nonhuman 
primates. Sci Transl Med. 2015;7(301):301ra132-
301ra132. 
18.  Zhu X, Liu Q, Du L, Lu L, Jiang S. Receptor-
binding domain as a target for developing SARS 
vaccines. J Thorac Dis. 2013;5:7. 
19.  Chen W-H, Strych U, Hotez PJ, Bottazzi ME. The 
SARS-CoV-2 Vaccine Pipeline: an Overview. Curr 
Trop Med Rep. 2020;7(2):61-64. 
20.  Lan J, Yao Y, Deng Y, et al. Recombinant Receptor 
Binding Domain Protein Induces Partial Protective 
Immunity in Rhesus Macaques Against Middle East 
Respiratory Syndrome Coronavirus Challenge. 
EBioMedicine. 2015;2(10):1438-1446. 
21.  Turista DDR, Islamy A, Kharisma VD, Ansori 
ANM. Distribution of COVID-19 and Phylogenetic 
Tree Construction of SARS-CoV-2 in Indonesia. J 
Pure Appl Microbiol. 2020;14(suppl 1):1035-1042.
22.  Wang Y, Tai W, Yang J, et al. Receptor-binding 
domain of MERS-CoV with optimal immunogen 
dosage and immunization interval protects human 
transgenic mice from MERS-CoV infection. Hum 
Vaccines Immunother. 2017;13(7):1615-1624. 
23.  Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel 
S. Coronavirus membrane fusion mechanism 
offers a potential target for antiviral development. 
Antiviral Res. 2020;178:104792. 
24.  Lai AL, Millet JK, Daniel S, Freed JH, Whittaker 
GR. The SARS-CoV Fusion Peptide Forms an 
Extended Bipartite Fusion Platform that Perturbs 
Membrane Order in a Calcium-Dependent Manner. 
J Mol Biol. 2017;429(24):3875-3892. 
25.  Malik YA. Properties of Coronavirus and SARS-
CoV-2. Malays J Pathol. 2020;42(1):3-11.
26.  Li S, Lin L, Wang H, et al. The Epitope Study on 
the SARS-CoV Nucleocapsid Protein. Genomics 
Proteomics Bioinformatics. 2003;1(3):198-206. 
27.  Leung DTM, Tam FCH, Ma CH, et al. Antibody 
Response of Patients with Severe Acute Respiratory 
Syndrome (SARS) Targets the Viral Nucleocapsid. 
J Infect Dis. 2004;190(2):379-386. 
28.  Kim TW, Lee JH, Hung C-F, et al. Generation and 
Characterization of DNA Vaccines Targeting the 
Nucleocapsid Protein of Severe Acute Respiratory 
Syndrome Coronavirus. J Virol. 2004;78(9):4638-
4645.
29.  Collisson E. Cytotoxic T lymphocytes are critical in 
the control of infectious bronchitis virus in poultry. 
Dev Comp Immunol. 2000;24(2-3):187-200. 
30.  Seo SH, Pei J, Briles WE, Dzielawa J, Collisson 
EW. Adoptive Transfer of Infectious Bronchitis 
Virus Primed αβ T Cells Bearing CD8 Antigen 
Protects Chicks from Acute Infection. Virology. 
2000;269(1):183-189.
31.  Astuti I, Ysrafil. Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2): An overview of 
viral structure and host response. Diabetes Metab 
Syndr Clin Res Rev. 2020;14(4):407-412. 
32.  Neuman BW, Kiss G, Kunding AH, et al. A structural 
analysis of M protein in coronavirus assembly and 
morphology. J Struct Biol. 2011;174(1):11-22. 
33.  Liu J, Sun Y, Qi J, et al. The Membrane Protein of 
Severe Acute Respiratory Syndrome Coronavirus 
Acts as a Dominant Immunogen Revealed by 
a Clustering Region of Novel Functionally and 
Structurally Defined Cytotoxic T‐Lymphocyte 
Epitopes. J Infect Dis. 2010;202(8):1171-1180.
34.  Pang H, Liu Y, Han X, et al. Protective humoral 
responses to severe acute respiratory syndrome-
associated coronavirus: implications for the design 
of an effective protein-based vaccine. J Gen Virol. 
2004;85(10):3109-3113. 
35.  Arndt AL, Larson BJ, Hogue BG. A Conserved 
Domain in the Coronavirus Membrane Protein 
Tail Is Important for Virus Assembly. J Virol. 
2010;84(21):11418-11428. 
36.  Nieto-Torres JL, DeDiego ML, Verdiá-Báguena 
C, et al. Severe Acute Respiratory Syndrome 
Coronavirus Envelope Protein Ion Channel Activity 
Promotes Virus Fitness and Pathogenesis. Denison 
MR, ed. PLoS Pathog. 2014;10(5):e1004077. 
37.  Sharma A, Krause A, Worgall S. Recent 
developments for Pseudomonas vaccines. Hum 
Vaccin. 2011;7(10):999-1011. 
38.  Ansori ANM, Kharisma VD, Antonius Y, Tacharina 
 Indian Journal of Forensic Medicine & Toxicology, October-December 2021, Vol. 15, No. 4      2803
MR, Rantam FA. Immunobioinformatics analysis 
and phylogenetic tree construction of severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) 
in Indonesia: spike glycoprotein gene. J Teknol 
Lab. 2020;9(1):13-20. 
39.  Takashima Y, Osaki M, Ishimaru Y, Yamaguchi 
H, Harada A. Artificial Molecular Clamp: A Novel 
Device for Synthetic Polymerases. Angew Chem 
Int Ed. 2011;50(33):7524-7528. 
40.  Liu H, Su D, Zhang J, et al. Improvement of 
Pharmacokinetic Profile of TRAIL via Trimer-Tag 
Enhances its Antitumor Activity in vivo. Sci Rep. 
2017;7(1):8953. 
41.  Pardi N, Hogan MJ, Porter FW, Weissman D. 
mRNA vaccines — a new era in vaccinology. Nat 
Rev Drug Discov. 2018;17(4):261-279. 
42.  Zhang C, Maruggi G, Shan H, Li J. Advances in 
mRNA Vaccines for Infectious Diseases. Front 
Immunol. 2019;10:594.
43.  Jahanafrooz Z, Baradaran B, Mosafer J, et al. 
Comparison of DNA and mRNA vaccines against 
cancer. Drug Discov Today. 2020;25(3):552-560. 
44.  Yurina V. Live Bacterial Vectors—A Promising 
DNA Vaccine Delivery System. Med Sci. 
2018;6(2):27.
45.  Azmi F, Ahmad Fuaad AAH, Skwarczynski M, 
Toth I. Recent progress in adjuvant discovery for 
peptide-based subunit vaccines. Hum Vaccines 
Immunother. 2014;10(3):778-796. 
46.  Ahmed SF, Quadeer AA, McKay MR. Preliminary 
Identification of Potential Vaccine Targets for the 
COVID-19 Coronavirus (SARS-CoV-2) Based 
on SARS-CoV Immunological Studies. Viruses. 
2020;12(3):254.
